Theravance Biopharma (TBPH) Total Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Total Current Liabilities data on file, last reported at $31.8 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $31.8 million, up 0.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.8 million (up 0.87% YoY), and the FY2025 annual result was $38.3 million, up 19.38% from the prior year.
• Total Current Liabilities slipped to $31.8 million in Q1 2026 per TBPH's latest filing, from $38.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $142.1 million in Q3 2022 and troughed at $21.7 million in Q1 2024.
• A 5-year average of $37.8 million and a median of $31.5 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities plunged 82.15% in 2023, then jumped 138.09% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $28.7 million in 2022, then slipped by 13.75% to $24.8 million in 2023, then advanced by 29.55% to $32.1 million in 2024, then gained by 19.38% to $38.3 million in 2025, then fell by 17.04% to $31.8 million in 2026.
• Business Quant data shows TBPH's Total Current Liabilities at $31.8 million in Q1 2026, $38.3 million in Q4 2025, and $37.4 million in Q3 2025.